Clinical trial NCT01123850: CopiOs Posterolateral Fusion Procedure
Official title: A Prospective Study Assessing Clinical Outcomes and Radiographic Results After the Use of CopiOs(R) Bone Void Filler (BVF)Sponge in a Posterolateral Fusion Procedure (PLF).
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Spondylolisthesis
Stenosis
Keywords: CopiOs
Degenerative spondylolisthesis,
stenosis with instability, or
degenerative disc disease as diagnosed by radicular signs and/or imaging studies
Lead sponsor: Zimmer Biomet
Sponsor class: INDUSTRY
First posted: 2010-05-14
Enrollment: 45
Sex: ALL
Minimum age (years): 21
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To compare radiographic data collection from patients undergoing instrumented PLF with CopiOs(R) BVF or instrumented PLF with autologous bone and to assess overall clinical outcomes. Patients will serve as self controls.

Detailed description: This is a prospective, counter-balanced study involving 85 subjects at up to 8 investigative centers. Each subject will be an appropriate candidate for an instrumented PLF and will meet the inclusion and exclusion criteria. All subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study. Data will be collected pre-operatively, operatively and post-operatively at six and twelve months.

The study objectives include: Radiographic success of CopiOs is non-inferior to autograft with clear evidence of bridging bone. Radiographic analysis will be used to show that CopiOs works as well as autograft when comparing the rate of fusion at 6 and 12 months. The CT scan (12 month) will show that CopiOs works as well as autograft when comparing the fusion mass between the transverse processes. Additionally, clinical success will be determined by an improvement of 15 percentage points using the Oswestry Disability Index and maintenance or improvement in the motor and sensory components of the neurological assessment from preoperative to postoperative. Since patients serve as self-controls there will be no clinical success comparisons between the groups. Rather, clinical success will be measured on overall improvement based on patient outcomes.

Eligibility criteria: Inclusion Criteria:

* Patient must be skeletally mature; between the ages of 21 and 75
* Patients having degenerative spondylolisthesis, stenosis with instability, or degenerative disc disease as diagnosed by radicular signs and/or imaging studies
* Patients will be medically indicated for a single-level, instrumented PLF between L2 and S1 per their surgeon
* Patient must be willing and able to comply with study requirements, including all necessary study related paperwork and follow-up visits

Exclusion Criteria:

* Use of iliac crest bone graft;
* Any previous lumbar spinal surgeries at indicated level;
* Any medical or physical condition that would preclude the potential benefit of spinal surgery;
* Use of a dynamic stabilization systems;
* Sites where stresses on void will exceed the load strength of fixation of hardware;
* Segmental defects;
* Significantly impaired vascularity proximal to the surgical site;
* Sites in direct contact with articular space;
* Soft tissue deficit not allowing closure;
* Active systemic or local infection;
* Severe degenerative bone disease;
* Patients with osteoporosis who are actively under treatment;
* Extreme obesity, as defined by NIH Clinical Guidelines Body Mass Index (BMI\>40 kg/m2);
* Active malignancy;
* Patients with a history of multiple allergies;
* Patients with known allergies to bovine collagen;
* Hypercalcemia;
* Pregnancy;
* Mental illness;
* Alcohol or drug abuse;
* Incarceration.

Primary outcomes:
measure: Fusion Assessment
timeFrame: 6 M, 12 M
Secondary outcomes:
measure: Outcome Measure - Pain, Life Quality, Satisfaction
timeFrame: PreOp, Surgery, 6M, 12M
Other outcomes:
Locations:
city: Orlando
country: United States
facility: Florida Hospital
state: Florida
city: Belleville
country: United States
facility: Neurological Surgery of Southern Illinois
state: Illinois
city: Indianapolis
country: United States
facility: Indiana Orthopedic Center
state: Indiana
city: Las Cruces
country: United States
facility: Las Cruces Orthopaedic Associates
state: New Mexico
city: East Syracuse
country: United States
facility: Upstate Bone and Joint Center
state: New York
city: Temple
country: United States
facility: Scott and White Healthcare
state: Texas
Study officials:
References: